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Tamoxifen resistance presents a prominent clinical challenge in endocrine therapy for hormone sensitive
breast cancer. However, the underlying mechanisms that contribute to tamoxifen resistance are not fully
understood. In this study, we established a tamoxifen resistant MCF-7 cell line (MCF-7-Tam-R) by
continuously incubating MCF-7 cells with 4-OH-tamoxifen. We found that melanoma cell adhesion
molecule (MCAM/CD146), a unique epithelial-to-mesenchymal transition (EMT) inducer, was signiﬁ-
cantly up-regulated at both mRNA and protein levels in MCF-7-Tam-R cells compared to parental MCF-7
cells. Mechanistic research demonstrated that MCAM promotes tamoxifen resistance by transcriptionally
suppressing ERa expression and activating the AKT pathway, followed by induction of EMT. Elevated
MCAM expression was inversely correlated with recurrence-free and distant metastasis-free survival in a
cohort of 4142 patients with breast cancer derived from a public database, particularly in the subgroup
only treated with tamoxifen. These results demonstrate a novel function of MCAM in conferring
tamoxifen resistance in breast cancer. Targeting MCAM might be a promising therapeutic strategy to
overcome tamoxifen resistance in breast cancer patients.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Breast cancer is the most common malignancy in women
worldwide. Approximately 70e75% of breast tumors are estrogen
receptor (ER) and/or progesterone receptor (PR)-positive [1].
Endocrine therapy plays an important role in decreasing the
recurrence risk for this subset of patients with localized disease,
and yields clinical beneﬁt in advanced or metastatic disease [2,3].ospital of Shantou University
yt), guoj_zhang@yahoo.com
Ireland Ltd. This is an open accessTamoxifen is the most widely used agent for this indicationwith
excellent efﬁcacy, particularly for younger patients in adjuvant
settings [4]. Unfortunately, acquired resistance to tamoxifen
signiﬁcantly compromises effectiveness and presents a prominent
challenge in the endocrine therapy of hormone-sensitive breast
cancer patients. Despite initial responses to tamoxifen treatment,
about 30% of ER-positive patients ultimately develop local recur-
rence and present with distant metastases, which is frequently
associated with reduced survival [5]. A number of studies have
suggested that the mechanism that confers tamoxifen resistance
includes modiﬁcation or loss of ERa expression [6], deregulation of
signal transduction pathways, aberrant expression of speciﬁc driver
proteins, and abnormality in tamoxifen metabolic activity [7,8].
Chronic exposure of breast cancer cells to tamoxifen during the
course of treatment may promote adaptive changes and is oftenarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
Y.-K. Liang et al. / Cancer Letters 386 (2017) 65e7666accompanied by acquisition of aggressive biological behaviors,
including epithelial-to-mesenchymal transition (EMT) [9] and
stem-cell like features [10], resulting in enhanced invasive and
metastatic properties as well as increased self-renewal capacity
[11,12]. Accumulating evidence has revealed that acquired
tamoxifen-resistant breast cancer cells share signatures pertinent
to an invasive phenotype and increased migratory capacity, which
are driven in part through a variety of altered oncogenic signaling
transduction pathways, including ERa [13e15], PI3K/AKT/mTOR,
and CDK4/CDK6 [11,16e18].
MCAM, also called CD146 or MUC18, was ﬁrst identiﬁed in
malignant melanoma and was shown to be a key oncogene driving
melanoma progression andmetastasis [19]. A previous study found
that MCAM was highly expressed in triple-negative breast cancer
and acted as a unique EMT activator [20]. Subsequent quantitative
proteomic analysis suggested that a MCAM-driven EMT processes
in breast cancer cells occurred via negative regulation of ERa [21].
Clinically, emerging evidence consistently indicates that MCAM
confers a poor prognosis in patients with breast cancer [22,23].
However, the relationship between MCAM and endocrine response
in breast cancer has not yet been reported.
In this study, we explored the role of MCAM on tamoxifen
resistance and underlying mechanisms of how MCAM inﬂuence
ERa status in ER-positive MCF7 cells. Our preliminary ﬁndings
demonstrated that MCAM is aberrantly up-regulated in MCF-7-
Tam-R cells. Additionally, we evaluated the association between
MCAM expression and survival in breast cancer patients, specif-
ically in ER-positive patients receiving tamoxifen treatment from
an online database.
Materials and methods
Cell culture and establishment of Tam-R cells
Breast cancer cell lines MCF-7, T47D, SKBR-3, MDA-MB-231, and BT-549 were
obtained from American Type Culture Collection (ATCC). MCF-7 cells were cultured
in Dulbecco's Modiﬁed Eagle Medium (DMEM) supplemented with 10% fetal bovine
serum (FBS) (Gibco, CA, USA) and 1% pen/strep (Gibco, CA, USA). MCF-7 cells
resistant to tamoxifen treatment (MCF-7-Tam-R) were generated by culturing
parental MCF-7 cells continuously in medium containing 10% FBS supplemented
with 1 mM 4-hydroxytamoxifen (SigmaeAldrich, St Louis, MO, USA) for 3 months
and then at 3 mM for at least 9 months. All cell lines were maintained in a humidiﬁed
incubator at 37 C and 5% CO2.
Cell proliferation assay
For cell proliferation assay and IC50 determination, 5  103 cells were plated in
96-well plates. After 24 h, the cells were incubated with different concentrations of
4-OH-TAM (SigmaeAldrich, St Louis, MO, USA) as indicated in the ﬁgure legend. The
vehicle (0.1% ethanol) was used as a control. Each treatment was performed with 5
replicates in 100 mL media. Media was changed with fresh medium containing the
same supplements every 2 days. Cell proliferation was measured using the Cell
Counting Kit (CCK-8) (Beyotime Institute of Biotechnology, Jiangsu, China) according
to the manufacturer's instructions. Brieﬂy, 10 mL of CCK-8 was added to 100 mL
medium per well and incubated at 37 C and 5% CO2 for 2 h. After that cell counts
were determined by measuring absorbance at 450 nm using a 96-well format plate
reader.
Plasmids, small interfering RNA, and transfection
The empty vector pCMV-GFP and pCMV-GFP-MCAM plasmids were purchased
from Sino Biological Inc. (Beijing, China). The ERa promoter (928 bp upstream of
exon1 and extending to þ72 bp) was sub-cloned upstream (NheI/BglII sites) of a
luciferase reporter gene. pRL-SV40 (Promega, WI, USA) was used as control vector to
normalize transfection efﬁciency. Small interference RNAs (siRNA) were purchased
from GenePharma Company (Suzhou, China). Cells were transfected with plasmids
or siRNA using Lipofectamine 2000 (Life Technology, NY, USA) according to the
manufacturer's instructions. To generate stable MCF-7-MCAM cells, 2 days after
transfection 0.5 mg/ml puromycin was added to the medium for selection.
Western blot analysis
Western blotting was performed as described previously [24]. In brief, cells were
lysed in RIPA buffer with 1 mM phenylmethylsulfonyl ﬂuoride and phosphatase
inhibitors (5 mM sodium orthovanadate), and protein lysates were separated by 8%SDS-PAGE and transferred onto a PVDF membrane. The membrane was blocked in
5% skim milk and subsequently incubated with primary antibodies listed in
Supplemental Table 1 at 4 C overnight. After washing three times each for 5 min in
Tris-buffered saline containing 1% Tween-20 (TBST), the membrane was then
incubated with peroxidase-conjugated goat anti-mouse IgG or goat anti-rabbit IgG
and visualized using super ECL detection reagent (Applygen, Beijing, China).
RNA isolation and qRT-PCR
Total RNA was isolated from cells using TRIzol (Life Technology, NY, USA)
following the manufacturer's instructions and stored at 80 C. Reverse transcrip-
tion was performed using the PrimeScript™ RT reagent kit (Takara Bio Inc., Dalian,
China) according to the manufacturer's instructions. qRT-PCR was performed using
SYBR Premix Ex Taq (Takara Bio Inc., Dalian, China) on a CFX96 Real-time PCR
Detection System (Bio-Rad, CA, USA). Primer sequences for qPCR are listed in
Supplemental Table 2. PCR reactions were performed at 50 C for 2min and 95 C for
2 min, followed by 40 cycles of 95 C for 15 s and 60 C for 1 min.
Immunohistochemical staining for cells
Cells were cultured on Millicell EZ 8-well glass slides (Merck Millipore, Ger-
many) and ﬁxed with 4% paraformaldehyde for 10 min at 4 C. Cells were per-
meabilized with 0.5% Triton X-100 for 20 min followed by blocking for 20 min with
10% BSA and incubated with primary antibody overnight at 4 C. In the negative
controls, primary antibodies were omitted and replaced by PBS. Sections were
treated with peroxidase-conjugated goat anti-rabbit or anti-mouse anti-bodies at
room temperature for 1 h. After washing with PBS, the chromogen DABwas added to
cells for 3e10 min depend on antibodies. Counterstaining was performed using
hematoxylin for 3 min.
Transwell migration and invasion assay
Cell culture inserts (8 mM pore size; BD, CA, USA) and Matrigel invasion cham-
bers (BD, CA, USA) were used according to the manufacturer's instructions. A total of
5 104 cells in serum-free mediumwere inoculated in the upper chamber after cells
were serum-starved for 24 h. Complete mediumwas added to the bottom chamber.
Cells were stained with 0.1% crystal violet after 72 h culture. Each assay was per-
formed in triplicate. The number of cells from 5 ﬁelds in each well was counted by 2
investigators.
Immunoﬂuorescence assay
Cells were cultured on Millicell EZ 8-well glass slides (Merck Millipore, Ger-
many) and ﬁxed with 4% paraformaldehyde for 10 min at 4 C. Permeabilized cells
were treated with 0.5% Triton X-100 for 20 min followed by blocking for 20minwith
10% BSA and incubated with primary antibody overnight at 4 C. Fixed cells were
incubated with secondary antibodies (Alexa Fluor 594 donkey anti-rabbit IgG, Alexa
Fluor 488 donkey anti-mouse IgG) at room temperature for 1 h. Slides were
mounted in Vectashield with DAPI (Life Technology, NY, USA). Images were visual-
ized with an immunoﬂuorescence microscope (Carl Zeiss, Jena, Germany).
Wound-healing assay
Cell motility was quantiﬁed using in vitro wound-healing assay. Cells were
seeded at ﬂat-bottom 6-well plates into a subconﬂuent cell monolayer and serum
starved for 12 h. Wounds were then scratched in the middle of each well using a
100 mL pipette tip. Medium with 10% FBS was replaced by serum-free media after
washing twice with PBS, and then incubated at 37 C in 5% CO2. Wound width was
measured in 5 randomly selected ﬁelds by light microscopy at the time point of 0-
hour and 72-hour.
Luciferase assay
We performed luciferase assay with the Dual Luciferase Reporter Assay System
(Promega, WI, USA) as indicated by the manufacturer's instructions and measured
luciferase activity 48 h after transfection. MCF-7 cell were transiently transfected
with the ERa promoter luciferase reporter vector in the presence of pCMV-MCAM or
control vectors in 24-well plates. For all reporter assays, pRL-SV40 was co-
transfected as a control vector to normalize transfection efﬁciency.
Analysis of MCAM expression in patients with breast cancer
A publicly accessible online clinical database (http://kmplot.com) was used to
assess the association between MCAMmRNA expression and survival in 4142 breast
cancer patients [25]. KaplaneMeier survival curves according to MCAM (Affymetrix
probe set 211042_x_at) expression status, together with hazard ratio (HR) and log-
rank P values were displayed.
Statistical analysis
Data from at least 3 independent experiments are expressed as the mean ± SD.
Student's t-test was used to determine statistically signiﬁcant differences, and
P < 0.05 was considered statistically signiﬁcant unless otherwise speciﬁed.
Fig. 1. MCF-7-Tam-R cells are resistant to 4-OH-tamoxifen treatment and show enhanced motility and invasive behaviors. (A) Cell viability was examined using the cell counting
kit-8 (CCK-8) assay after treatment with 10 different concentrations of 4-OH-tamoxifen (0 mM, 0.01 mM, 0.1 mM, 1 mM, 5 mM, 10 mM, 15 mM, 20 mM, 25 mM, 30 mM, 35 mM) for 72 h. (B)
Proliferation rate of MCF-7 and MCF-7-Tam-R cells treated with 5 mM 4-OH-tamoxifen. Cell viability was measured once per day using the CCK8 assay. (C)Morphology of MCF-7 and
MCF-7-Tam-R cells. (D and E) Representative micrographs (200) and quantitative migration transwell assays. MCF-7 or MCF-7-Tam-R cells were counted in 5 random ﬁelds. (F and
G) Representative micrographs (200) and quantitative migration transwell assays. MCF-7 or MCF-7-Tam-R cells were counted in 5 random ﬁelds. Data represent the mean of
triplicate experiments ± SEM. ***P < 0.001 versus control.
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Fig. 2. MCAM is highly expressed in MCF-7-Tam-R cells. (A) Relative mRNA level of MCAM, ERa, E-cadherin, vimentin were detected by RT-PCR in MCF-7 and MCF-7-Tam-R cells. (B)
Western blot analysis in MCF-7 and MCF-7-Tam-R cells. (C and D) Immunoﬂuorescence of MCF-7 and MCF-7-Tam-R cells stained with anti-MCAM (green signal) and anti-E-
cadherin (red signal) antibody. DAPI (blue), 40 , 6-diamidino-2-phenylindole.
Y.-K. Liang et al. / Cancer Letters 386 (2017) 65e7668KaplaneMeier survival curve, HRwith 95% conﬁdence intervals and log-rank P value
were calculated and plotted in R using Bio-conductor packages.Results
MCF-7 cells with acquired tamoxifen resistance exhibit enhanced
cell motility and invasive behavior
To validate tamoxifen resistance in established MCF-7-Tam-R
cells, the IC50 of cells was determined using a CCK8 viability assay at
different 4-OH-tamoxifen concentrations for 72 h. The IC50 was
2.18 mM for parental MCF-7 cells and 17.09 mM for MCF-7-Tam-R
cells (Fig. 1A). When both MCF-7-Tam-R and MCF-7 cells were
treated with 5 mM 4-OH-tamoxifen, MCF-7-Tam-R cell viability was
signiﬁcantly higher than that of MCF-7 cells, demonstratingMCF-7-
Tam-R cell resistance to tamoxifen (Fig. 1B).
We next investigated whether acquisition of the tamoxifen
resistance phenotype was accompanied by morphological changes.
The MCF-7 cells displayed characteristics typical of epithelial cells,
growing in tightly packed cobblestone-like clusters. In contrast,
MCF-7-Tam-R cells displayed a ﬁbroblast-like morphology and
appeared to have lost tight cellecell contact (Fig. 1C). Given that
MCF-7-Tam-R cells had undergone a distinctive mesenchymal-like
morphology, we hypothesized that these cells would display
enhanced motile and invasive behaviors. Using transwell assays we
observed that MCF-7-Tam-R cells had signiﬁcantly higher migra-
tion and invasion capacities compared with MCF-7 parental cells
(P < 0.001, Fig. 1DeG). These data indicate that MCF-7-Tam-R cells
acquired EMT-like properties and more invasive behaviors
compared with parental MCF-7 cells.MCAM and pAKT increased while ERa is decreased in MCF-7-Tam-R
cell lines
We examined the expression of ERa and key molecules in the
AKT pathway in MCF-7-Tam-R cells. As shown in Fig. 2A and B, both
ERa mRNA and protein levels decreased in MCF-7-Tam-R cells
compared to MCF-7 cells. pAKT expression was activated, while
PTEN levels were diminished in MCF-7-Tam-R cells. In addition,
expression of the epithelial marker E-cadherin was decreased,
while the mesenchymal marker vimentin was up-regulated.
Real-time PCR analysis revealed that MCAM mRNA levels were
20-fold higher in MCF-7-Tam-R cells than in control cells and that
MCAM protein expression was dramatically up-regulated (Fig. 2A
and B). We further investigated the expression and localization of
MCAM together with the key epithelial marker E-cadherin in both
cells by immunoﬂuorescence. MCAM protein levels were up-
regulated in MCF-7-Tam-R cells and mainly localized in the cyto-
plasm, while E-cadherin was decreased compared with MCF-7
(Fig. 2C and D). These results indicate that MCAM up-regulation
in MCF-7-Tam-R cells may contribute to tamoxifen resistance in
breast cancer.MCAM is highly expressed in ERa negative breast cancer cell lines
and inversely associates with epithelial markers
To further investigate the potential role of MCAM in breast
cancer, we determined its expression in breast cancer cell lines.
Western blotting showed that MCAMwas highly expressed in ERa-
negative basal-like phenotype MDA-MB-231 and BT-549 or HER2-
positive SKBR3 breast cancer cells. These cells also expressed the
Fig. 3. MCAM is overexpressed in ERa-negative breast cancer cell lines. (A) Expression of MCAM, ERa, E-cadherin, and vimentin was detected by Western blot in various breast
cancer cell lines. MCAM (B), ERa (C), E-cadherin (D), and vimentin (E) mRNA levels were determined by real-time PCR in breast cancer cell lines. (F) Protein levels of MCAM, b-
catenin, and E-cadherin were determined by Western blot in MCF-7 cells transfected with pCMV-MCAM or control vectors as indicated. (G) MCAM, b-catenin, and E-cadherin were
detected by immunohistochemistry. (H) Immunoﬂuorescence staining of MCF-7 cells transiently transfected with the pCMV-GFPeMCAM vector using anti-MCAM (green signal)
and anti-E-cadherin (red signal) antibodies. DAPI.
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Y.-K. Liang et al. / Cancer Letters 386 (2017) 65e76 71ﬁbroblast/stromal cell marker vimentin. In contrast, MCAM protein
expression was almost not detectable in luminal epithelial
phenotype breast cancer cells, which express ERa and the epithelial
cell marker E-cadherin (Fig. 3A). Real-time PCR analyses also
demonstrated similar expression proﬁles of these markers at the
mRNA level (Fig. 3BeE).
We found a signiﬁcant decrease in levels of the epithelial marker
E-cadherin in cells that overexpress MCAM (Fig. 3F). In contrast, the
mesenchymal transcription factor b-catenin was signiﬁcantly up-
regulated (Fig. 3F and G). To further evaluate whether MCAM af-
fects EMT markers, we transiently transfected MCF-7 cells with
pCMV-GFP-MCAM or pCMV-GFP plasmids, which both express
green ﬂuorescence protein. Immunoﬂuorescence staining revealed
that E-cadherin levels were signiﬁcantly decreased in cells
expressing MCAM compared with parental or control transfected
cells. Thus, overexpression of MCAM signiﬁcantly reduced expres-
sion of epithelial markers and up-regulated mesenchymal markers.
MCAM induces epithelialemesenchymal transition and tamoxifen
resistance in MCF-7 cells
Tumor cells with acquired EMT are generally characterized by
morphological changes and typically exhibit enhanced cellular
migratory and invasive behaviors. To investigate the effects of
MCAM on EMT, we established stable transfected pCMV-MCAM
plasmids in MCF-7 cells. MCAM-expressing MCF-7 cells showed
characteristics of cellular scattering with a ﬁbroblast-like
morphology in contrast to MCF-7 cells, which maintained a
cobblestone phenotype with strong cellecell adhesion (Fig. 4A).
Moreover, over-expression of MCAM signiﬁcantly enhanced
migration and invasion capacity, when compared to parental MCF-
7 cells (p < 0.001, Fig. 4BeF). Together, these ﬁndings demonstrate
that MCAM can induce EMT in MCF-7 cells.
To determine whether MCAM expression is correlated with
tamoxifen resistance, we treated MCF-7-MCAM and MCF-7 cells
with 0e20 mmol/L 4-hydroxytamoxifen in vitro for 72 h. MCF-7-
MCAM with high MCAM expression had higher survival rates at 5
and 10 mmol/L 4-OH-TAM compared with control MCF-7 cells
(Fig. 4G). We next investigated if down-regulation of endogenous
MCAM would result in reversed tamoxifen sensitivity in MCF-7-
Tam-R cells. We transfected MCAM RNAi (siMCAM) or siNC in
MCF-7-Tam-R cells and treated them with different 4-OH-TAM
concentrations. In the siMCAM group, cell viability was reduced by
30% at 5 mmol/L 4-OH-TAM, 60% at 10 mmol/L 4-OH-TAM, and 40% at
20 mmol/L 4-OH-TAM compared with the control group (Fig. 4H).
Thus, these results show that overexpression of MCAM induces
tamoxifen resistance inMCF-7 cells, on the other hand, inhibition of
endogenous MCAM in generated MCF-7-Tam-R cells restores
sensitivity to tamoxifen treatment.
MCAM suppresses ERa and activates AKT pathway in MCF-7 cells
Negative correlation between expression of MCAM and ERa in
breast cancer cells led us to investigate whether MCAM regulated
ERa directly at transcriptional level. Western blotting and real-time
PCR analysis showed that ERa was markedly suppressed by over-
expressing MCAM at both protein and mRNA levels (Fig. 5A and B).Fig. 4. MCAM induces epithelial mesenchymal transition and tamoxifen resistance in MCF-
microscopy (200). (B) Representative micrographs (40) of the wound healing assay in M
width at 0 and 72 h. Wound healing lengths were measured in 5 random ﬁelds. (C and D) Rep
MCAM and MCF-7 cells; 5 random ﬁelds were counted. (E and F) Representative micrograp
cells or MCF-7 cells were counted in 5 random ﬁelds. (G) Cell viability was examined using
72 h in MCF-7 and MCAM-expressing MCF-7 cells. (H) Cell viability was examined using the
in MCF-7, MCF-7-Tam-R, and siMCAM transfected MCF-7-Tam-R cells. Data represent the mImmunoﬂuorescence staining revealed that ERa protein level was
signiﬁcantly decreased in the MCF-7-MCAM cells compared with
parental or control transfected cells (Fig. 5C).
To further analyze the mechanism of ERa regulation by MCAM,
we cloned the ERa promoter (928 bp upstream of exon1, extending
to þ72 bp) prior to a luciferase reporter gene and evaluated ERa
promoter activity. When co-transfected with 100 ng and 200 ng
MCAM plasmid, ERa promoter activity decreased by approximately
25% and 50%, respectively (Fig. 5D). This result implies that MCAM
transcriptionally regulates ERa expression. Previous studies have
shown that Slug suppresses ERa expression by binding to the E-box
of the ERa promoter [26]. As expected, the transcription factor Slug
was up-regulated when MCAM was overexpressed in MCF-7 cells
(Fig. 5A). Moreover, we found that the inhibitory effect of MCAM on
ERa promoter was rescued by co-transfection of RNAi against Slug
(Fig. 5E). Therefore, we postulated thatMCAM repressed ERa by up-
regulating Slug expression.
We then examined the impact of MCAM on the AKT pathway,
which has previously been reported to contribute to tamoxifen
resistance in breast cancer. Western blot analysis showed that
pAKT, but not total AKT, expression was dramatically restored,
while PTEN expression was decreased when transfected with
MCAM in MCF-7 cells (Fig. 5F). Immunohistochemical staining also
displayed that MCAM down-regulated ERa while up-regulated
pAKT (Fig. 5G). These ﬁndings indicate that MCAM is a pivotal
mediator of tamoxifen resistance by modulating ERa status and the
AKT pathway in breast cancer.Elevated MCAM expression predicts poor survival in breast cancer
patients, especially in the subgroup treated only with tamoxifen
To elucidate the association of MCAM with clinical outcomes in
patients with breast cancer, especially in those with ER-positive
tumors who received tamoxifen treatment, we used an online
database to determine the association between MCAM mRNA
expression and clinical endpoints in 4142 breast cancer patients
[25,27]. In all patients, high MCAM expression was signiﬁcantly
associated with shortened overall survival (OS, P ¼ 1.1e-07,
HR ¼ 1.91) as well as reduced recurrence-free survival (RFS,
P ¼ 2.5e-14, HR ¼ 1.56) and distant metastasis-free survival (DMFS,
P ¼ 4.4e-06, HR ¼ 1.61) (Fig. 6AeC).
Of note, in patients with ER-positive tumors, increased expres-
sion of MCAM was signiﬁcantly associated with a poorer OS
(P ¼ 0.00017, HR ¼ 2.25). In addition, a similar correlation was also
observed between MCAM status and RFS (P ¼ 0.00011, HR ¼ 1.41)
and DMFS (P ¼ 0.0028, HR ¼ 1.74) (Fig. 6DeF), which implies that
MCAM might be an important indicator of tumor relapse and
distant metastasis in ER-positive breast cancer patients.
Subgroup analysis of the patients receiving only tamoxifen
treatment demonstrated that elevated expression of MCAM was
signiﬁcantly correlated with shortened durations across all three
survival endpoints, including OS (P ¼ 0.016, HR ¼ 2.78), RFS
(P ¼ 0.014, HR ¼ 1.47), and DMFS (P ¼ 0.00096, HR ¼ 1.88)
(Fig. 6GeI). Thus, MCAM appears to be a strong marker of poor
prognosis in patients treated with tamoxifen.7 cells. (A) Morphology of MCF-7-MCAM and MCF-7 cells evaluated by phase contrast
CF-7 and MCAM-transfected MCF-7 cells. Cells were photographed to measure wound
resentative micrographs (200) and quantitative migration transwell assays of MCF-7-
hs (200) and quantitative invasion transwell assays. Stably expressing MCAM MCF-7
the CCK-8 assay after treatment with 4 different concentrations of 4-OH-tamoxifen for
CCK-8 assay after treatment with 4 different concentrations of 4-OH-tamoxifen for 72 h
ean of triplicate experiments ± SEM. ***P < 0.001 versus control.
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Fig. 5. Over-expression of MCAM suppresses ERa and activates the AKT pathway. (A) Protein levels of MCAM, ERa, and pAKT (B)MCAM and ERamRNA expression were determined
by Western blot and real-time PCR in MCF-7 cells transfected with pCMV-MCAM or control vectors as indicated. (C) Immunoﬂuorescence staining of MCF-7 cells transiently
transfected with the pCMV-GFPeMCAM vector using anti-MCAM (green signal) and anti-ERa (red signal) antibodies, DAPI (blue signal). (D, E) Luciferase activity was measured in
MCF-7 cells by co-transfection of an ERa promoter reporter vector with an MCAM expression plasmid with or without Slug RNAi, fold change was expressed with Renilla luciferase
as an internal control. (F) Protein levels of MCAM, PTEN, AKT, and pAKT were determined by Western blot in MCF-7 cells transfected with pCMV-MCAM or control vectors as
indicated. (G) ERa and pAKT were immunohistochemically stained in MCF-7 cells transfected with pCMV-MCAM or control vectors as indicated, bar represents 50 mm. Data
represent the mean of triplicate experiments ± SEM. **P<0.01 versus control, ***P < 0.001 versus control.
Fig. 6. The prognostic effect of high and low expression of MCAM in patients with breast cancer and tamoxifen-treated patients. (A) OS (n ¼ 1117, P ¼ 1.1e-07, HR ¼ 1.91), (B) RFS
(n ¼ 3554, P ¼ 2.5e-14, HR ¼ 1.56), (C) DMFS (n ¼ 1609, P ¼ 4.4e-06, HR ¼ 1.61) for all patients. (D) OS (n ¼ 377, P ¼ 0.00017, HR ¼ 2.25), (E) RFS (n ¼ 1802, P ¼ 0.00011, HR ¼ 1.41),
(F) DMFS (n ¼ 577, P ¼ 0.0028, HR ¼ 1.74) for ER-positive patients. (G) OS (n ¼ 65, P ¼ 0.016, HR ¼ 2.78), (H) RFS (n ¼ 762, P ¼ 0.014, HR ¼ 1.47), (I) DMFS (n ¼ 555, P ¼ 0.00096,
HR ¼ 1.88) for tamoxifen-treated patients.
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Fig. 7. Proposed schematic model for tamoxifen resistance mediated by MCAM in ERa
positive breast cancer cells. MCAM activates AKT signaling directly or via inhibition of
PTEN, and transcriptionally down-regulates ERa via activating Slug, ultimately
resulting in tamoxifen resistance in endocrine therapy sensitive breast cancer cells.
Y.-K. Liang et al. / Cancer Letters 386 (2017) 65e7674Discussion
Tamoxifen has been used to treat both pre- and post-
menopausal breast cancer patients for over 40 years and remains
a cornerstone in endocrine therapy for breast cancer [28]. However,
intrinsic or acquired resistance to tamoxifen presents a particular
clinical concern [29]. Although resistance to tamoxifen can be
counteracted by switching to aromatase inhibitors [30] or fulves-
trant [31], underlying aggressive biological behaviors of the tumor,
often with a variety of altered signaling transduction [32], are
associated with an unfavorable prognosis [33]. The present study,
for the ﬁrst time, demonstrates that MCAM is overexpressed in
MCF-7-Tam-R cells compared to tamoxifen-sensitive counterparts.
MCAM expression was inversely correlated with ERa expression in
a subset of breast cancer cells. In addition, MCAM silencing signif-
icantly reversed tamoxifen resistance into a sensitive phenotype.
These ﬁndings imply that MCAM plays a crucial role in the devel-
opment of tamoxifen resistance and may be an essential determi-
nant of tamoxifen resistance in breast cancer.
In this study, we established and characterized a MCF-7 cell
model resistant to tamoxifen to investigate the potential function of
MCAM in the acquisition of tamoxifen resistance in breast cancer.
Compared to parental MCF-7 cells, MCF-7-Tam-R cells displayed
changes in phenotypic features with enhanced motility and invasive
behaviors, as well as altered expression of EMTmarkers, including E-
cadherin, vimentin, and b-catenin, all of which indicate that tumor
cells are undergoing the EMT process. This observation is also sup-
ported by earlier studies reporting that EMT is a prominent deter-
minant of tamoxifen resistance in a breast cancer cell model [9,34].
MCAM was ﬁrst discovered in metastatic melanoma with
markedly high abundance, but was shown to be absent in normal
melanin cells or pigment nevus. MCAM has been extensively
implicated in a variety of oncogenic signaling transduction path-
ways, such as NF-kB [35], VEGF/VEGFR [36e38], and PI3K/AKT [39],
and acts as a key driver of progression and metastasis in multiple
cancer types, including breast and lung cancers [19,40]. In the
present study, forced expression of MCAM promoted invasive be-
haviors in MCF-7 cells, similar to the characteristics observed in
MCF-7-Tam-R cells. Studies further showed that overexpression of
MCAM in MCF-7 cells induced tamoxifen resistance, while MCAM
silencing signiﬁcantly reversed tamoxifen resistance in MCF-7-
Tam-R cells. The mechanisms contributing to tamoxifen resis-
tance are likely multifactorial, but remain largely unknown.
Our study showed that MCAM is primarily overexpressed in
basal-like or Her-2 overexpression, but not luminal, breast cancer
cell subtypes, and we found an inverse correlation between MCAM
and ERa expression levels in breast cancer cell lines. Given that the
effects of tamoxifen are primarily mediated through its binding to
ER and the status of ERa has long been considered the primary
determinant of a clinical response to tamoxifen, loss of ER expres-
sion could confer resistance to therapy [41]. MCAM could suppress
ERa at the transcription level by up-regulating Slug expression. A
previous study by Li et al. suggested that Slug binds directly to E-
boxes in the ERa promoter region to control ERa activation and
function. Knockdown of Slug increased sensitivity to tamoxifen
treatment in MCF-Tam-R cells [26]. In addition, Zeng et al.
demonstrated that MCAM overexpression contributed to activation
of Slug and RhoA and induced EMT in breast cancer [20]. Therefore,
we postulated that MCAM transcriptionally down-regulates ERa
expression partially by up-regulating Slug.
In addition, many studies have demonstrated that AKT is a
critical factor in conferring resistance to tamoxifen [42,43]. Acti-
vation of the PI3K/AKT pathway is recognized as one of the
mechanisms contributing to endocrine resistance [44]. We
demonstrated that pAKT was dramatically activated inMCF-7-Tam-R cells. We also speciﬁcally showed that forced expression of
MCAM suppressed PTEN expression and induced pAKT activity. The
results are consistent with a previous study by Li et al. showing that
MCAM was constitutively implicated in the AKT signaling pathway
[39]. Moreover, another study has indicated that MUC1-C, a
member of the same cellular adhesion family as MCAM (MUC-18),
exerted its function by activating the PI3K/AKT pathway in the
development of breast cancer [45]. Taken together, our result
implied that MCAM also induced tamoxifen resistance by activating
the AKT pathway, at least in part.
Furthermore, overexpression of MCAM was signiﬁcantly corre-
lated with poor RFS and DMFS in a large public clinical microarray
database of 4142 breast cancer patients. Especially, elevated
expression of MCAMwas signiﬁcantly correlated with poor OS, RFS,
or DMFS in a cohort of ER-positive breast cancer patients. Inter-
estingly, overexpression of MCAMwas signiﬁcantly correlated with
shorter OS, RFS, or DMFS in the cohort of patients who only
received tamoxifen treatment. Therefore, MCAM might serve as a
unique predictive marker of tamoxifen resistance for breast cancer.
In conclusion, our study demonstrates that, MCAM confers
tamoxifen resistance and is an important modulator of EMT-like
properties in breast cancer cells. We explored a novel mechanism
of acquiring tamoxifen resistance mediated by MCAM, at least in
part, through suppressing ERa expression and activating the AKT
pathway (Fig. 7). We further show that High MCAM overexpression
is associated with a poor prognosis in ER-positive patients who
received tamoxifen therapy. Therefore, targeting MCAM is a
promising therapeutic strategy to overcome tamoxifen resistance
in breast cancer patients.
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